Endocrine and Metabolic Consultants

06/16/2026

We begin screening on Novo's new triple agent weight loss compound next week in people without diabetes who want to lose 25% or more of their starting weight. It's an 8 month trial where the triple agent compound will be compared with Wegovy (~22%) or a placebo (~14%). Link below, please call office with any questions at 301-770-7373, ask for the 8649 trial.https://pmc.ncbi.nlm.nih.gov/articles/PMC12304053/

04/13/2026

We are beggining recruitment for the AMAZE 8 trial investigating a new dual agent weight loss IP from Novo. The comparator is semaglutide (Wegovy). The trial is for people with type 2 diabetes treated with diet or pills who have a BMI of >27. You can not have been treated with a GLP-1 within the last year. If interested, please call our office at 301-770-7373.

03/11/2026

We will begin screening for another weight loss trial in June 2026. This will be a 36 week trial for people with a BMI of >30 without diabetes. The IP is a triple agent (GLP1-GIP-amylin) compound. Please call our office at 301-770-7373 for more details. Ask for someone from the Study Team.

12/17/2025

We just got approved for a 112 week weight loss trial (AMAZE-8) for people with type 2 diabetes. There are two very unusual, in a good way, aspects.... #1)There is no placebo group. #2) They only want people who are interested in losing 25% of their starting weight. It's not listed on clinical trials. gov yet, so give us a call in the office for more details at 301-770-7373. Ask for someone from the study team. Use of a GLP-1 within the last year is an exclusion. The study number is NNC0487-0111.

This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any....

11/15/2025

We have several upcoming trials in 2026 on some double and triple agent weight loss investigational products. Enrollment includes people with and without diabetes. Please call our office at 301-770-7373 for details.

03/03/2025

We have two weight loss trials starting in April and May 2025. One is for people with type 1 diabetes, the other is for people with type 2 diabetes, as well as those without diabetes. Both require a BMI of >30 or >27 with one weight related co-morbidity. Call us at 301-770-7373 to discuss.

04/11/2023

I am pre-screening for a 1-2 year weight loss trial. If your BMI is 28 kg/m or greater, and you're potentially interested, please call our office re details. Ask to speak with someone re the Lilly Weight Loss Trial. Enrollment begins in June (16 spots).

04/08/2023

We have 4 spots left in a 3 month insulin pump trial. If you have type 2 diabetes, and are using multiple daily insulin injections, you may qualify. Please call 301-770-7373 for more information.

06/02/2022

We were just selected for a very interesting Medtronic trial using their InPen. Anyone treated with multiple daily injections is eligible. People with type 1 and type 2. Link below. Call our office for information at 301-770-7373.

Use of the Guardian™ Connect System With Smart Connected Devices - Full Text View.

03/22/2022

We are beginning to recruit for two trials of once weekly insulin in people the type 1 (July) and type 2 (April). Please call our office at 301-770-7373 to discuss.

Insulin was first isolated in 1921 and developed as a therapeutic agent in the 1920s. The initial crude preparations were injected multiple times daily because